Fee for Using a Material Threat Medical Countermeasure Priority Review Voucher in Fiscal Year 2020
| Citation | 84 FR 51597 |
| Record Number | 2019-21198 |
| Published date | 30 September 2019 |
| Section | Notices |
| Court | Food And Drug Administration |
Federal Register, Volume 84 Issue 189 (Monday, September 30, 2019)
[Federal Register Volume 84, Number 189 (Monday, September 30, 2019)]
[Notices]
[Pages 51597-51599]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-21198]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2019-N-007]
Fee for Using a Material Threat Medical Countermeasure Priority
Review Voucher in Fiscal Year 2020
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) is
announcing the fee rate for using a material threat medical
countermeasure (MCM) priority review voucher for fiscal year (FY) 2020.
The Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended by the
21st Century Cures Act (Cures Act), authorizes FDA to determine and
collect material threat MCM priority review user fees for certain
applications for review of human drug products when those applications
use a material threat MCM priority review voucher. These vouchers are
awarded to the sponsors of material threat MCM applications that meet
all the requirements of this program and upon FDA approval of such
applications. The amount of the fee for using a material threat MCM
priority review voucher is determined each FY based on the difference
between the average cost incurred by FDA to review a human drug
application designated as priority review in the previous FY, and the
average cost incurred in the review of an application that is not
subject to priority review in the previous FY. This notice establishes
the material threat MCM priority review fee rate for FY 2020 and
outlines the payment procedures for such fees.
FOR FURTHER INFORMATION CONTACT: Melissa Hurley, Office of Financial
Management, Food and Drug Administration, 4041 Powder Mill Rd., Rm.
61075, Beltsville, MD 20705-4304, 240-402-4585.
SUPPLEMENTARY INFORMATION:
I. Background
Section 3086 of the Cures Act (Pub. L. 114-255) added section 565A
to the FD&C Act (21 U.S.C. 360bbb-4a). In section 565A of the FD&C Act,
Congress encouraged development of material threat MCMs by offering
additional incentives for obtaining FDA approval of such products.
Under section 565A of the FD&C Act, the sponsor of an eligible material
threat MCM application (as defined in section 565A(a)(4)) shall receive
a priority review voucher upon approval of the material threat MCM
application. The recipient of a material threat MCM priority review
voucher may either use the voucher for a future human drug application
submitted to FDA under section 505(b)(1) of the FD&C Act (21 U.S.C.
355(b)(1)) or section 351(a) of the Public Health Service Act (42
U.S.C. 262(a)), or transfer (including by sale) the voucher to another
party. The voucher may be transferred (including by sale) repeatedly
until it ultimately is used for a human drug application submitted to
FDA under section 505(b)(1) of the FD&C Act or section 351(a) of the
Public Health Service Act. A priority review is a review conducted with
a Prescription Drug User Fee Act (PDUFA) goal date of 6 months after
the receipt or filing date, depending on the type of application.
Information regarding PDUFA goals is available at https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm511438.pdf.
The sponsor that uses a material threat MCM priority review voucher
is entitled to a priority review of its eligible human drug
application, but must pay FDA a material threat MCM priority review
user fee in addition to any user fee required by PDUFA for the
application. Information regarding the material threat MCM priority
review voucher program is available at: https://www.fda.gov/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMLegalRegulatoryandPolicyFramework/ucm566498.htm.
This notice establishes the material threat MCM priority review fee
rate for FY 2020 at $2,167,116 and outlines FDA's payment procedures
for material threat MCM priority review user fees. This rate is
effective on October 1, 2019, and will remain in effect through
September 30, 2020.
II. Material Threat Medical Countermeasure Priority Review User Fee for
FY 2020
FDA interprets section 565A(c)(2) of the FD&C Act as requiring that
FDA determine the amount of the material threat MCM priority review
user fee each fiscal year based on the difference between the average
cost incurred by FDA in the review of a human drug application subject
to priority review in the previous fiscal year, and the average cost
incurred by FDA in the review of a human drug application that is not
[[Page 51598]]
subject to priority review in the previous fiscal year.
A priority review is a review conducted with a PDUFA goal date of 6
months after the receipt or filing date, depending on the type of
application. Under the PDUFA goals letter, FDA has committed to
reviewing and acting on 90 percent of the applications granted priority
review status within this expedited timeframe. Normally, an application
for a human drug product will qualify for priority review if the
product is intended to treat a serious condition and, if approved,
would provide a significant improvement in safety or effectiveness. An
application that does not receive a priority designation receives a
standard review. Under the PDUFA goals letter, FDA has committed to
reviewing and acting on 90 percent of standard applications within 10
months of the receipt or filing date, depending on the type of
application. A priority review involves a more intensive level of
effort and a higher level of resources than a standard review.
FDA is setting a fee for FY 2020, which is to be based on standard
cost data from the previous fiscal year, FY 2019. However, the FY 2019
submission cohort has not been closed out yet, thus the cost data for
FY 2019 are not complete. The latest year for which FDA has complete
cost data is FY 2018. Furthermore, because FDA has never tracked the
cost of reviewing applications that get priority review as a separate
cost subset, FDA estimated this cost based on other data that the
Agency has tracked. The Agency expects all applications that received
priority review would contain clinical data. The application categories
with clinical data that for which FDA tracks the cost of review are:
(1) New drug applications (NDAs) for a new molecular entity (NME) with
clinical data and (2) biologics license applications (BLAs).
The total cost for FDA to review NME NDAs with clinical data and
BLAs in FY 2018 was $335,338,639. There was a total of 74 applications
in these two categories (53 NME NDAs with clinical data and 21 BLAs).
(Note: These numbers exclude the President's Emergency Plan for AIDS
Relief NDAs; no investigational new drug review costs are included in
this amount.) Forty-eight of these applications (35 NDAs and 13 BLAs)
received priority review and the remaining 26 received standard
reviews. Because a priority review compresses a review schedule that
ordinarily takes 10 months into 6 months, FDA estimates that a
multiplier of 1.67 (10 months / 6 months) should be applied to non-
priority review costs in estimating the effort and cost of a priority
review as compared to a standard review. This multiplier is consistent
with published research on this subject, which supports a priority
review multiplier in the range of 1.48 to 2.35 (Ref. 1). Using FY 2018
figures, the costs of a priority and standard review are estimated
using the following formula:
(48 [alpha] x 1.67) + (26 [alpha]) = $335,338,639
where ``[alpha]'' is the cost of a standard review and ``[alpha] times
1.67'' is the cost of a priority review. Using this formula, the cost
of a standard review for NME NDAs and BLAs is calculated to be
$3,158,804 (rounded to the nearest dollar) and the cost of a priority
review for NME NDAs and BLAs is 1.67 times that amount, or $5,275,203
(rounded to the nearest dollar). The difference between these two cost
estimates, or $2,116,399, represents the incremental cost of conducting
a priority review rather than a standard review.
For the FY 2020 fee, FDA will need to adjust the FY 2018
incremental cost by the average amount by which FDA's average costs
increased in the 3 years prior to FY 2019, to adjust the FY 2018 amount
for cost increases in FY 2019. That adjustment, published in the
Federal Register on August 1, 2019 (see 84 FR 37882), setting FY 2020
PDUFA fees, is 2.3964 percent for the most recent year, not compounded.
Increasing the FY 2018 incremental priority review cost of $2,116,399
by 2.3964 percent (or 0.023964) results in an estimated cost of
$2,167,116 (rounded to the nearest dollar). This is the material threat
MCM priority review user fee amount for FY 2020 that must be submitted
with a priority review voucher for a human drug application in FY 2020,
in addition to any PDUFA fee that is required for such an application.
III. Fee Schedule for FY 2020
The fee rate for FY 2020 is set out in table 1:
Table 1--Material Threat Medical Countermeasure Priority Review Schedule
for FY 2020
------------------------------------------------------------------------
Fee rate for FY
Fee category 2020
------------------------------------------------------------------------
Application submitted with a material threat MCM $2,167,116
priority review voucher in addition to the normal
PDUFA fee.............................................
------------------------------------------------------------------------
IV. Implementation of Material Threat Medical Countermeasure Priority
Review User Fee
Under section 565A(c)(4)(A) of the FD&C Act, the priority review
user fee is due upon submission of a human drug application for which
the priority review voucher is used. Section 565A(c)(4)(B) of the FD&C
Act specifies that the application will be considered incomplete if the
priority review user fee and all other applicable user fees are not
paid in accordance with FDA payment procedures. In addition, section
565A(c)(4)(C) specifies that FDA may not grant a waiver, exemption,
reduction, or refund of any fees due and payable under this section of
the FD&C Act.
The material threat MCM priority review fee established in the new
fee schedule must be paid for any application with a priority review
voucher that is received on or after October 1, 2019. This fee must be
paid in addition to any other fee due under PDUFA. Payment must be made
in U.S. currency by electronic check, check, bank draft, wire transfer,
credit card, or U.S. postal money order payable to the order of the
Food and Drug Administration. The preferred payment method is online
using electronic check (Automated Clearing House (ACH) also known as
eCheck). Secure electronic payments can be submitted using the User
Fees Payment Portal at https://userfees.fda.gov/pay. (Note: Only full
payments are accepted. No partial payments can be made online.) Once
you search for your invoice, select ``Pay Now'' to be redirected to
Pay.gov. Note that electronic payment options are based on the balance
due. Payment by credit card is available for balances that are less
than $25,000. If the balance exceeds this amount, only the ACH option
is available. Payments must be made using U.S. bank accounts as well as
U.S. credit cards.
FDA has partnered with the U.S. Department of the Treasury to use
Pay.gov, a web-based payment application, for online electronic
payment. The Pay.gov feature is available on the FDA website after the
user fee ID number is generated.
[[Page 51599]]
If paying by paper check, the user fee identification (ID) number
should be included on the check, followed by the words ``Material
Threat Medical Countermeasure Priority Review.'' All paper checks must
be in U.S. currency from a U.S. bank made payable and mailed to: Food
and Drug Administration, P.O. Box 979107, St. Louis, MO 63197-9000.
If checks are sent by a courier that requests a street address, the
courier can deliver the checks to: U.S. Bank, Attention: Government
Lockbox 979107, 1005 Convention Plaza, St. Louis, MO 63101. (Note: This
U.S. Bank address is for courier delivery only. If you have any
questions concerning courier delivery, contact the U.S. Bank at 314-
418-4013. This telephone number is only for questions about courier
delivery). The FDA post office box number (P.O. Box 979107) must be
written on the check. If needed, FDA's tax identification number is 53-
0196965.
If paying by wire transfer, please reference your unique user fee
ID number when completing your transfer. The originating financial
institution may charge a wire transfer fee. If the financial
institution charges a wire transfer fee, it is required to add that
amount to the payment to ensure that the invoice is paid in full. The
account information is as follows: U.S. Dept. of the Treasury, TREAS
NYC, 33 Liberty St., New York, NY 10045, Account Number: 75060099,
Routing Number: 021030004, SWIFT: FRNYUS33
V. Reference
The following reference is on display at the Dockets Management
Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm.
1061, Rockville, MD 20852, and is available for viewing by interested
persons between 9 a.m. and 4 p.m., Monday through Friday; it is not
available electronically at https://www.regulations.gov as this
reference is copyright protected. FDA has verified the website address,
as of the date this document publishes in the Federal Register, but
websites are subject to change over time.
1. Ridley, D.B., H.G. Grabowski, and J.L. Moe, ``Developing
Drugs for Developing Countries,'' Health Affairs, vol. 25, no. 2,
pp. 313-324, 2006, available at: https://www.healthaffairs.org/doi/full/10.1377/hlthaff.25.2.313.
Dated: September 25, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019-21198 Filed 9-27-19; 8:45 am]
BILLING CODE 4164-01-P
